TITLE

Insulin degludec in Phase 3 trials

PUB. DATE
May 2011
SOURCE
Clinical Cardiology Alert;May2011 Pharmacology, p2
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports that insulin degludec, an ultralong-acting insulin, is currently undergoing Phase 3 trials, and discusses a study which concluded that insulin degludec provides glycemic control without adverse events (AEs) and may reduce dosing frequency.
ACCESSION #
60492841

 

Related Articles

  • Insulin degludec in Phase 3 trials.  // Clinical Oncology Alert;May2011 Supplement 2, p2 

    The article reports that insulin degludec, an ultralong-acting insulin, is currently undergoing Phase 3 trials, and discusses a study which concluded that insulin degludec provides glycemic control without adverse events (AEs) and may reduce dosing frequency.

  • Diabetes.  // Geriatrics;Jul99, Vol. 54 Issue 7, p12 

    Reports on the approval of rosiglitazone maleate (Avandia) for the treatment of type 2 diabetes as monotherapy or in combination with metformin by the United States Food and Drug Administration. How rosiglitazone works in the body; Effects of the drug on blood sugar levels; Recommended starting...

  • Exenatide + rosiglitazone added to metformin.  // Clinical Cardiology Alert;Aug2010 Supplement, p16 

    The article discusses research being done on the efficacy of exenatide and rosiglitazone added to metformin for controlling glucose, with reference to a study by R. A. DeFronzo and colleagues, published in the 2010 issue of the journal "Diabetes Care."

  • Exenatide + rosiglitazone added to metformin. Kuritzky, Louis // Critical Care Alert;Aug2010 Primary Care Supp, p16 

    The article presents information on the treatment of type 2 diabetes with adequate lifestyle and metformin.

  • Exenatide + rosiglitazone added to metformin.  // Clinical Oncology Alert;Aug2010 Supplement, p16 

    The article discusses research being done on the effect of exenatide (EXE) and rosiglitazone (ROS) when added to metformin to control glucose in patients with type 2 diabetes (DM2) in reference to a study by R. A. DeFronzo et al. published in the 2010 issue of "Diabetes Care."

  • Self-monitoring of blood glucose was not cost-effective in non-insulin- treated type 2 diabetes. Simon, J. // Evidence Based Medicine;Dec2008, Vol. 13 Issue 6, p171 

    Design: cost-effectiveness analysis of a randomised controlled trial with 1-year follow-up (Diabetes Glycaemic Education and Monitoring [DiGEM]. Setting: 48 general practices in the UK. Patients: 453 patients {mean age 66 y, 57% men} who had non-insulin-treated type 2 diabetes with haemoglobin...

  • Dipeptidyl peptidase-4 inhibitor in a patient with end-stage renal disease and type 2 diabetes. Mee Onn Chai; Noble-Bell, Georgia // Journal of Renal Nursing;Jul2015, Vol. 7 Issue 4, p180 

    No abstract available.

  • Degludec, a New Ultralong- acting Basal Insulin for Diabetes.  // Clinical Oncology Alert;Jul2012 Clinical Briefs, p13 

    The article reports a study by AJ Garber and colleagues which revealed that type 2 diabetic patients on degludec insulin, a recently submitted drug for FDA approval, had 20 percent fewer hypoglycemic episodes than glargine, indicating that its approval may provide a superior hypoglycemia risk.

  • Bromocriptine in Diabetes Mellitus - A Review. Pandita, Aakriti; Azher, Idrees // Asian Student Medical Journal;2013, Vol. 13 Issue 6, p1 

    The article presents information on the approval of the drug QR-bromocriptine by the U.S. Food and Drug Administration (FDA) for the treatment of type 2 diabetes mellitus. It mentions that the drug is an antidiabetic that helps in reducing plasma glucose, triglycerides and cardiovascular events....

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics